Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 6;16(8):1142-1148.
doi: 10.7150/ijms.34541. eCollection 2019.

Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression

Affiliations

Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression

Jun Ji et al. Int J Med Sci. .

Abstract

Background: The aims of this study were to investigate the expression pattern of CDK12 protein in gastric cancer, and to analyze the correlations of CDK12 expression between CD8+ cell density and CCL12 expression. Methods: Eighty-six paired tumor and non-tumor samples were collected from patients who underwent radical surgery and had pathological confirmed gastric adenocarcinoma. Immunohistochemistry was used to assess CDK12 expression and CD8+ cell density. Expression of CDK12 and CCL21 mRNA was detected by quantitative reverse transcription-polymerase chain reaction. Results: CDK12 expression in gastric tumor tissues was significantly higher than it in paired non-tumor tissues (P<0.001). High expression of CDK12 was identified in 43 cases (50%), and it was significantly correlated with Lauren's classification (diffuse type) and number of metastatic lymph nodes (≥15). High CDK12 protein level indicated a relative poorer overall survival than patients with CKD12 low expression, while it was not identified as an independent prognostic factor. Median number of CD8+ cells in tumor tissues was 51 (range: 0-292). Number of CD8+ cells was positively correlated with CDK12 expression score in tumor tissues (r=0.243, P=0.024). Positive correlation was also found between CDK12 and CCL21 mRNA expression (r=0.419, P=0.017). Conclusion: High CDK12 expression was detected in gastric cancer which was correlated with malignant phenotypes and worse outcome. Positive correlations of CD8+ cell number and CCL21 mRNA expression with CDK12 level were identified.

Keywords: CCL21; CD8+ cells; CDK12; Gastric cancer; lymph node metastasis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Expression of CDK12 in gastric cancer and survival curve of patients with different CDK12 expression. CDK12 was located in cell nuclear. Expression of CDK12 in non-tumor tissue (A) was lower than its in paired tumor tissue (B). Representative images of CDK12 staining with different score were showed. The intensity scores of image C to F were all 3. The percentage scores were (C) 2; (D) 3; (E) 4; and (F) 5. All images at 400× magnification. G: Patients with CDK12 high expression had a shorter median overall survival than those with CDK12 low expression (40.1 months vs. 50.0 months, P=0.025).
Figure 2
Figure 2
CDK12 expression and CD8+ cells in gastric cancer. Positive correlation between CDK12 expression and CD8+ cells number was identified in gastric cancer. CDK12 high expression (A) and CD8+ cells number over 35 (B) were detected in one gastric tumor sample, while CDK12 low expression (C) and CD8+ cells number less than 35 (D) in another tumor sample.
Figure 3
Figure 3
Correlation of CDK12 with number of CD8+ cells and CCL21. A: Correlation analysis between CDK12 staining score and number of CD8+ cells; B: Correlation analysis between CDK12 and CCL21 mRNA expression.

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS. et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2) Lancet. 2015;385:977–1010. - PMC - PubMed
    1. Chivu-Economescu M, Matei L, Necula LG, Dragu DL, Bleotu C, Diaconu CC. New therapeutic options opened by the molecular classification of gastric cancer. World journal of gastroenterology. 2018;24:1942–61. - PMC - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. - PubMed
    1. Zhou C, Feng X, Yuan F, Ji J, Shi M, Yu Y. et al. Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis. Cancer management and research. 2018;10:3945–54. - PMC - PubMed